BRAF p.V600E

About

Gene context: BRAF

Biomarker Type: Somatic Variant

Present: True

Chromosome: 7

Start Position: 140453136

End Position: 140453136

Reference Allele: A

Alternate Allele: T

Cdna Change: c.1799T>A

Protein Change: p.V600E

Variant Annotation: Missense

Exon: 15

Rsid: rs113488022

Hgvsg: 7:g.140453136A>T

Legacy biomarker representation, assumes GRCh37 / hg19 genome build.

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (+)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (+)	BRAF p.V600E	Melanoma	Vemurafenib